Procedures
tumor, Head and Neck Cancers
ADVERSE EVENT, TUMOR, ADVERSE EVENT, SOLID TUMORS, HEAD AND NECK CANCER
The optimal doses of the combination of C with olaparib were determined on the basis of a phase I trial in solid tumors (After surgery, all patients were reevaluated by a multidisciplinary tumor board and if necessary were referred for postoperative radiotherapy according to current clinical guidelines (NCCN, guidelines for Head and Neck Cancers). Patients were followed for 3 months after the date of second biopsy or surgery, or after the last dose of study treatment, or the initiation of the next antineoplastic treatment if that occurred earlier. Adverse events were graded according to the NCI Common Terminology Criteria for Adverse Events V. 4.0 scale.The details for the assays and image analysis are summarized in the 